New Drug Shows Promise in Weight Loss Without Nausea

Imagine being able to shed pounds using a medication that doesn’t come with the unpleasant side effects of nausea. Recent studies suggest that might actually be a reality.

Researchers from the University of Pennsylvania, the University of Kentucky, and other institutions have discovered a new approach to appetite suppression and obesity treatment. Their experimental drug shows potential effectiveness without the nausea often linked to semaglutide, which is an active ingredient in popular weight-loss medications like Ozempic and Wegovy. Initial animal trials indicate that this new drug is functioning as expected.

Semaglutide and similar drugs work by mimicking the GLP-1 hormone, which plays a crucial role in regulating insulin and hunger. Although these medications have proven effective for weight loss, they come with significant gastrointestinal side effects. This highlights the ongoing need for better obesity treatments, according to Caroline Geisler, a lead author of the study and assistant professor at the University of Kentucky’s College of Pharmacy.

Geisler and her team have focused on a specific method for tackling obesity, using a protein known as octadecaneuropeptide, or ODN. This protein is generated by glia—cells in the brain that support neurons—but they also seem to influence our hunger signals.

Geisler explained, “We’ve learned that glia have an important role in sensing and signaling the body’s status. By targeting this glial signaling molecule, we hope to activate various energy-regulating pathways in the brain, steering clear of the unpleasant side effects like nausea.”

In their studies, researchers initially delivered ODN directly to the hindbrain of rats. The outcome? The treated rats not only lost weight but also showed improved blood sugar levels. When researchers blocked ODN signaling, the rats exhibited a diminished response to GLP-1 treatment, hinting that ODN might be partly responsible for its effects.

Moreover, the team tested an experimental drug derived from ODN, named TDN, on mice, rats, and shrews. Results showed that TDN enhanced blood sugar control in mice and induced weight loss in rats without causing nausea or vomiting. None of the animals displayed any unwanted reactions related to heart rate, movement, or temperature.

Geisler remarked, “This research demonstrates for the first time that a smaller version of ODN can be effective in improving body weight and metabolic regulation without side effects.”

Although these findings, published in Science Translational Medicine, serve as an early proof of concept, many questions remain about how ODN operates in the brain to manage appetite and blood sugar. The researchers believe ODN-based drugs could potentially be further refined for medical application. Early indications suggest TDN resulted in consistent weight loss in animals for at least a week.

The researchers are optimistic that this new class of drugs could rival or even exceed the efficacy of current GLP-1 therapies, while being easier to tolerate. They are now gearing up for the development of these drugs for human testing, with an encouraging timeline suggesting clinical trials may start within two years.

It’s worth noting that these researchers aren’t the only ones aiming to introduce improved treatments for obesity and diabetes. After all, who wouldn’t want a weight loss solution that doesn’t require the use of a barf bag?